Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06818058
PHASE2

TAR-0520 Gel in EGFR Inhibitor-induced Folliculitis

Sponsor: Tarian Pharma

View on ClinicalTrials.gov

Summary

A Phase II, multicentric, randomized, double-blind, placebo-controlled, parallel- group trial to confirm the good safaty profile and to explore the preventive effect of topically applied TAR-0520 gel on folliculitis developed in metastatic colorectal cancer (mCRC) patients treated with monoclonal anti-EGFR antibodies.

Official title: A Phase II Multicentric, Randomized, Double-blind, Placebo-controlled Study of TAR-0520 Gel in EGFR Inhibitor-induced Folliculitis.

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2025-01-20

Completion Date

2026-09-30

Last Updated

2025-02-10

Healthy Volunteers

No

Interventions

DRUG

Brimonidine tartrate Gel

Once daily applications for 7 days

DRUG

Placebo gel (no Brimonidine tartrate)

Once daily applications for 7 days

Locations (3)

Hopital Privé Jean Mermoz

Lyon, France

Institut Paoli Calmette

Marseille, France

Centre Antoine Lacassagne

Nice, France